Figure 1.

The blood glucose lowering effect of SGK1 in insulin target organs. (A) In liver, SGK1 stimulates insulin signaling and inhibits FoxO3a activity, thus increasing insulin sensitivity and preventing hepatic injury. (B) In muscle, SGK1 facilitates SLC6A8 expression and inhibits FoxO3a activity, resulting in enhanced glucose uptake and glycogen synthesis. (C) In adipose tissue, SGK1 promotes Glut1 expression and suppresses FoxO1, which leads to intensified glucose uptake and lipid synthesis.